
==== Front
Ann OncolAnn. OncolannoncAnnals of Oncology0923-75341569-8041Oxford University Press 10.1093/annonc/mdz215mdz215CorrigendaUpdated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Hortobagyi G N Stemmer S M Burris H A Yap Y S Sonke G S Paluch-Shimon S Campone M Petrakova K Blackwell K L Winer E P Janni W Verma S Conte P Arteaga C L Cameron D A Mondal S Su F Miller M Elmeliegy M Germa C O’Shaughnessy J 11 2019 13 8 2019 13 8 2019 30 11 Therapy in breast cancer patients treated in the aTTom trial1842 1842 © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.2019This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
==== Body
Ann Oncol 2018; 29: 1541–1547 (doi: 10.1093/annonc/mdy155)

The following has been added to the ‘Disclosure’ section: “CLA reports fees for advisory work with Novartis Pharmaceuticals (specifically participation on a Steering Committee for a clinical trial).”

